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ABSTRACT
Objectives To explore the effects of tofacitinib—an
oral Janus kinase inhibitor for the treatment of
rheumatoid arthritis (RA)—with or without methotrexate
(MTX), on MRI endpoints in MTX-naive adult patients
with early active RA and synovitis in an index wrist or
hand.
Methods In this exploratory, phase 2, randomised,
double-blind, parallel-group study, patients received
tofacitinib 10 mg twice daily + MTX, tofacitinib 10 mg
twice daily + placebo (tofacitinib monotherapy), or MTX
+ placebo (MTX monotherapy), for 1 year. MRI
endpoints (Outcome Measures in Rheumatology Clinical
Trials RA MRI score (RAMRIS), quantitative RAMRIS
(RAMRIQ) and dynamic contrast-enhanced (DCE) MRI)
were assessed using a mixed-effect model for
repeated measures. Treatment differences with
p<0.05 (vs MTX monotherapy) were considered
signiﬁcant.
Results In total, 109 patients were randomised and
treated. Treatment differences in RAMRIS bone marrow
oedema (BME) at month 6 were −1.55 (90% CI −2.52
to −0.58) for tofacitinib + MTX and −1.74 (−2.72 to
−0.76) for tofacitinib monotherapy (both p<0.01 vs
MTX monotherapy). Numerical improvements in RAMRIS
synovitis at month 3 were −0.63 (−1.58 to 0.31) for
tofacitinib + MTX and −0.52 (−1.46 to 0.41) for
tofacitinib monotherapy (both p>0.05 vs MTX
monotherapy). Treatment differences in RAMRIQ
synovitis were statistically signiﬁcant at month 3,
consistent with DCE MRI ﬁndings. Less deterioration of
RAMRIS and RAMRIQ erosive damage was seen at
months 6 and 12 in both tofacitinib groups versus MTX
monotherapy.
Conclusions These results provide consistent
evidence using three different MRI technologies that
tofacitinib treatment leads to early reduction of
inﬂammation and inhibits progression of structural
damage.
Trial registration number NCT01164579.
INTRODUCTION
Inﬂammation of the synovium, particularly the
bone marrow, measured using MRI, has been
identiﬁed as a prognostic indicator of structural
joint damage in patients with rheumatoid arthritis
(RA).1–3 Inhibition of this damage at an early
stage in the disease course is desirable to limit dis-
ability4 and impact on general health and quality
of life.5
Tofacitinib is an oral Janus kinase ( JAK) inhibitor
for the treatment of RA. The efﬁcacy and safety of
tofacitinib 5 and 10 mg twice daily in patients with
active moderate-to-severe RA has been demonstrated
in randomised, double-blind, phase 26–10 and phase
311–16 studies of up to 24 months duration and in
open-label, long-term extension studies with up to
96 months of observation.17 The inhibition of struc-
tural damage in patients who received tofacitinib has
been shown using plain-ﬁlm radiography.14 15
MRI measures provide improved sensitivity
versus conventional radiography.18–20 Bone marrow
oedema (BME) and synovitis, measured using MRI,
have been shown to be highly sensitive to treatment
with conventional synthetic disease-modifying anti-
rheumatic drugs.21–25 However, few randomised
clinical trials have been published using MRI out-
comes as primary endpoints in patients with
early RA.21 23 26–28 The validated, semiquantitative
assessment of multiple pathologies using the
Outcome Measures in Rheumatology Clinical Trials
(OMERACT) RA MRI score (RAMRIS)29 has
become the standard for MRI trials.20 Quantitative
MRI measures offer the opportunity to improve on
the responsiveness of semiquantitative scoring.
Dynamic contrast-enhanced (DCE) MRI measure-
ments show strong correlation with histological
assessments of synovitis30 and have demonstrated
sensitivity in detecting therapy-induced changes in
synovitis in patients with early RA.31 32 Preliminary
work with active appearance modelling (AAM)33
RA MRI quantiﬁcation (RAMRIQ) of all involved
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joint tissues has suggested improved responsiveness over
RAMRIS.34
Patients with early RA have participated in previous studies of
tofacitinib, although the lowest mean duration of RA was
approximately 3 years.14 This is the ﬁrst study to explore the
effects of tofacitinib, as monotherapy or in combination with
methotrexate (MTX; vs MTX with placebo), on a range of
highly sensitive MRI endpoints, exclusively in patients with
early RA.
METHODS
Study design and conduct
This was an exploratory, phase 2, randomised, double-blind,
double-dummy, parallel-group study (A3921068;
NCT01164579), conducted at 24 centres in Central and Latin
America, Europe and the USA (25 October 2010–5 November
2013). Study end was the month 12 visit or early termination
for patients who discontinued.
Randomisation and treatment
At baseline, patients were randomised 1:1:1 using an automated
web/telephone randomisation system to tofacitinib 10 mg twice
daily with MTX, tofacitinib 10 mg twice daily with placebo
(tofacitinib monotherapy) or MTX with placebo (MTX mono-
therapy), for 12 months. Tofacitinib 10 mg twice daily was
administered orally as two 5 mg tablets twice daily. MTX was
administered orally in capsule form and titrated, if tolerated,
from 10 mg once weekly (4×2.5 mg capsules) to 15 mg once
weekly (6×2.5 mg capsules) at the end of month 1, and 20 mg
once weekly (8×2.5 mg capsules) at the end of month 2.
Figure 1 Patient disposition. aMean dose of methotrexate (MTX) at month 3 was 18.3 mg weekly; bmean dose of MTX at month 3 was 19.0 mg
weekly; ccould not attend scheduled visits due to work. AE, adverse event; BID, twice daily; N, number of patients in population or analysis set;
n, number of patients with an event.
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Placebo was matched to tofacitinib or MTX, according to
randomisation.
Patients
Eligible patients were aged ≥18 years; active RA (>6 tender/
painful joints/>6 swollen joints) of ≤2 years duration since diag-
nosis; erythrocyte sedimentation rate (ESR; Westergren method)
>28 mm/h, or C-reactive protein >7 mg/L. Patients were gener-
ally MTX-naive, although <3 weekly doses of MTX were per-
mitted after a 4-week washout of MTX, unless MTX had been
stopped due to a related adverse event (AE). Key eligibility cri-
teria included unequivocal evidence of ≥1 joint erosion on
hand/wrist radiographs (assessed at the study centre), plus clin-
ical evidence of synovitis (tenderness/pain or swelling, or both;
conﬁrmed by MRI at the study centre); see online supplemen-
tary materials for additional details.
Patients were excluded if they had received prior biological
disease-modifying antirheumatic drugs therapy; background
arthritis therapy is detailed in the supplementary materials.
Other exclusion criteria included replacement of an metacarpo-
phalangeal (MCP) or wrist joint within the index wrist or hand,
any contraindications to MRI (glomerular ﬁltration rate
<60 mL/min) or previous reaction to gadolinium contrast agent.
Patients with malignancies, lymphoproliferative disorder, evi-
dence of untreated latent or active tuberculosis, serious infection
≤6 months previous or infection requiring antimicrobial therapy
≤2 weeks previous were also excluded.
MRI assessments
MRIs were obtained at screening, and at months 1, 3, 6 and 12,
using clinical scanners (1.5 or 3.0 T). The same scanner was used
serially at any given centre. The contrast agent (0.1 mmol/kg
gadolinium) was administered intravenously with an infusion
pump. Images included coronal short tau inversion recovery
images, pre-contrast and post-contrast coronal T1-weighted
(T1w) fat-suppressed gradient echo images, axial DCE T1w gra-
dient echo images and post-contrast axial T1w fat-suppressed
spin echo images. Example images are shown in the online
supplementary materials.
RAMRIS
MRI BME, synovitis and bone erosions in the index hand (MCP
joints 1–5) and wrist were scored according to OMERACT
RAMRIS35 by one centralised reader blinded to time sequence
and treatment. The presence of any MRI-detected synovitis in
the studied joints that were evaluated with RAMRIS (wrist and
MCP joints 2–5) was used as MRI conﬁrmation of clinical
inclusion.
RAMRIQ
RAMRIQ measurements of BME, synovitis and erosions in the
wrist and MCP joints 2–5 were performed by Imorphics
(Manchester, UK) using automated methods. RAMRIQ
assessed the same pathologies and joints (excepting MCP1) as
RAMRIS, allowing for direct comparison of results obtained
Table 1 Summary of patient demographics and baseline characteristics
Parameter
Tofacitinib 10 mg twice
daily +MTX (N=36)
Tofacitinib 10 mg twice daily
monotherapy (N=36)
MTX monotherapy
(N=37)
Age, mean (SD) 47.8 (12.3) 50.8 (12.8) 47.8 (11.6)
Females, % 86.1 83.3 78.4
Mean duration of disease, years (range) 0.8 (0.1–2.2) 0.8 (0.1–8.5) 0.6 (0.1–1.9)
Positive for rheumatoid factor, n/N (%) 26/34 (76.5) 27/35 (77.1) 27/37 (73.0)
Anti-CCP positive, n/N (%) 27/34 (79.4) 27/35 (77.1) 30/37 (81.8)
Swollen joint count, mean (range) 13.4 (0.0–32.0) 15.3 (4.0–46.0) 14.4 (6.0–39.0)
Tender joint count, mean (range) 20.6 (0.0–57.0) 20.9 (4.0–53.0) 20.5 (9.0–52.0)
DAS28-4(ESR), mean (SD)* 6.3 (0.9) 6.5 (0.8) 6.4 (0.8)
HAQ-DI score, mean (SD)* 1.5 (0.8) 1.5 (0.6) 1.5 (0.7)
RAMRIS, mean (SD)†
BME 1.9 (3.7) 2.6 (3.7) 2.2 (5.1)
Synovitis 5.8 (3.8) 5.7 (3.5) 5.3 (3.9)
Bone erosions 9.4 (10.8) 7.5 (7.6) 12.2 (14.9)
RAMRIQ, mean (SD)*
BME 1.4 (2.8) 1.1 (2.7) 1.4 (2.7)
Synovitis 7750.4 (5432.8) 7971.8 (5510.1) 6980.7 (6304.8)
Bone erosions 1.6 (0.9) 1.6 (0.8) 1.9 (1.3)
DCE MRI NVox, mean (SD)‡ 3013.6 (3605.6) 2767.6 (2140.2) 3079.8 (3704.9)
Radiographic evaluations, mean (SD)†
van der Heijde mTSS 13.0 (21.7) 12.6 (26.0) 13.7 (26.0)
JSN component score 6.9 (13.3) 5.7 (15.0) 6.1 (12.7)
Erosion component score 6.1 (9.3) 6.9 (11.8) 7.6 (14.3)
Prior MTX, n (%)§ 0 (0.0) 2 (5.6) 4 (10.8)
Prior/concomitant systemic corticosteroids, n (%) 20 (55.6) 16 (44.4) 21 (56.8)
*Evaluable set: tofacitinib with MTX (N=36), tofacitinib monotherapy (N=36), MTX monotherapy (N=37).
†Evaluable set: tofacitinib with MTX (N=34), tofacitinib monotherapy (N=36), MTX monotherapy (N=37).
‡Evaluable set: tofacitinib with MTX (N=34), tofacitinib monotherapy (N=32), MTX monotherapy (N=32).
§Patients who had received <3 weekly doses of MTX were permitted to participate following a 4-week washout of MTX unless MTX had been stopped due to a related adverse event.
BME, bone marrow Oedema; CCP, cyclic-citrullinated peptide; DAS28-4(ESR), Disease Activity Score in 28 joints with 4 variables including erythrocyte sedimentation rate; DCE MRI,
dynamic contrast-enhanced MRI; HAQ-DI, Health Assessment Questionnaire-Disability Index; JSN, joint space narrowing; MTX, methotrexate; mTSS, van der Heijde modification of the total
Sharp score; NVox, number of enhancing voxels; RAMRIQ, quantitative rheumatoid arthritis MRI score; RAMRIS, rheumatoid arthritis MRI score.
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using the two methods. Bones were automatically identiﬁed in
pre-contrast, coronal T1 images using AAMs.33 36 Joint cap-
sules and soft tissues were also segmented with AAMs, provid-
ing consistent 3D regions of interest (ROI) for synovial
enhancement across all time points. Oedema volume was
deﬁned as non-erosion contrast-enhancing voxels inside the
bone. Synovial volume was calculated as voxels that enhance
within each ROI. Erosion volume was identiﬁed inside the
bone surfaces using voxel-based classiﬁcation. The volume of
BME and erosions was normalised to total bone volume for
statistical analysis.
DCE MRI
DCE MRI was captured for the wrist only. ROIs were deﬁned
by a radiologist within the area encompassing the distal radioul-
nar joint, the radiocarpal joint and the intercarpal–carpometa-
carpophalangeal joints. The number of enhancing voxels (NVox),
initial rate of enhancement (IRE) and maximum enhancement
(EMax),with plateau and washout patterns, were automatically
extracted from ROIs and the sum (NVox) or average (IRE and
EMax) of values across three user-deﬁned ROIs was determined
using the Dynamika software package (Image Analysis, London,
UK37).
Endpoints
The co-primary endpoints were change from baseline in
RAMRIS BME at month 6, and change from baseline in syno-
vitis at month 3, in wrist and MCP joints.
Changes from baseline in RAMRIS BME (except month 6),
synovitis (except month 3) and RAMRIS erosions at months 1,
3, 6 and 12 were assessed as secondary endpoints. Exploratory
endpoints included RAMRIQ assessments of BME, synovitis
and erosions; DCE MRI assessment of NVox, IRE and EMax; and
proportions of patients with/without progression based on
RAMRIS BME, synovitis and erosions.
Radiographic and clinical endpoints
Posteroanterior hand/wrist and anteroposterior foot radiographs
at baseline, month 6 and month 12, were assessed as secondary
endpoints using the van der Heijde modiﬁcation of the total
Sharp score (mTSS)—range 0–488, with higher scores indicating
greater structural joint damage.38 Radiographs were scored by a
centralised reader blinded to time sequence and treatment
received.
Clinical endpoints included American College of
Rheumatology (ACR)20, ACR50 and ACR70 responses; propor-
tion of patients achieving a Disease Activity Score (DAS28-4
Figure 2 Least squares (LS) mean change from baseline in wrist and metacarpophalangeal (MCP): (A) rheumatoid arthritis MRI score (RAMRIS)
bone marrow oedema (BME), (B) RAMRIS synovitis, (C) RAMRIS bone erosions, (D) quantitative rheumatoid arthritis MRI score (RAMRIQ) BME, (E)
RAMRIQ synovitis, (F) RAMRIQ bone erosions and wrist (G) dynamic contrast-enhanced MRI (DCE MRI) number of enhancing voxels (NVox)
(evaluable set). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs methotrexate (MTX) monotherapy, using a mixed-effect model for repeated
measures. MRI measurements were based on one hand (most symptomatic at baseline). RAMRIS and RAMRIQ scores relate to MRIs of the index
hand (MCP joints 1–5 and 2–5, respectively) and wrist. DCE MRI measurements relate to MRIs of the index wrist using regions of interest (ROIs)
deﬁned within the area encompassing the distal radioulnar joint, the radiocarpal joint and the intercarpal–carpometacarpophalangeal joints. BID,
twice daily.
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[ESR]) <2.6 (remission) or ≤3.2 (low disease activity); and
improvement from baseline in Health Assessment
Questionnaire-Disability Index (HAQ-DI) score ≥0.22.
Safety assessments
AEs and clinical laboratory abnormalities were recorded.
Medical Dictionary for Regulatory Activities V.16.1 was used.
Statistical analyses
This was an exploratory study. Sample size was determined by
change from baseline in RAMRIS BME score at month 6 and
RAMRIS synovitis score at month 3. A sample size of 30
patients per arm provided >80% probability to show a statis-
tical difference between arms at the two-sided α of 0.1.
Owing to an observed dropout rate of ∼20%, approximately
110 patients were to be enrolled to obtain 90 evaluable
patients for the primary endpoint analysis. Given the explora-
tory nature of the study, statistical signiﬁcance was assessed at
the 10% (two-sided) level. For reporting purposes, treatment
differences with p<0.05 (vs MTX monotherapy) were consid-
ered signiﬁcant.
The evaluable set—all patients who were randomised to study
treatment, received ≥1 dose of randomised investigational drug
and had available data at baseline and the indicated time point
—was used for the efﬁcacy analyses.
Primary and secondary continuous efﬁcacy endpoints were
assessed using a mixed-effect model for repeated measures, with
treatment arms as factors and baseline as a covariate.
Categorical endpoints were summarised by frequency (n, %).
For efﬁcacy endpoints, 90% CIs were included for the differ-
ence in proportions between the treatment arms. Procedures for
handling missing MRI values are provided in the online
supplementary materials.
Cumulative probability plots examined the distribution of
changes from baseline in OMERACT RAMRIS measures and
van der Heijde mTSS. The smallest detectable changes (SDCs)
for RAMRIS BME, synovitis and bone erosion measurements
were determined according to the method described by
Bruynesteyn et al39 using month 6 MRI data from 10 patients;
read twice by the same reader with >4 weeks between readings
to minimise any recall bias. SDCs for RAMRIS BME, synovitis
and erosion scores were 1.85, 2.77 and 0.85, respectively.
RESULTS
Patient disposition and demographics
Of 109 patients randomised, 36 received tofacitinib with MTX,
36 received tofacitinib monotherapy and 37 received MTX
monotherapy (ﬁgure 1). Baseline demographics and disease
characteristics were generally well balanced between groups
(table 1). Fewer patients who received MTX monotherapy
Figure 3 Cumulative probability plots for rheumatoid arthritis MRI score (RAMRIS) endpoints and van der Heijde modiﬁcation of the total Sharp
score (mTSS). The distribution of changes by percentile is shown. BID, twice daily; BME, bone marrow oedema; MCP, metacarpophalangeal; MTX,
methotrexate; SDC, smallest detectable change.
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completed the study (58.3% (n=21)) versus those who received
tofacitinib with MTX (77.8% (n=28)) or tofacitinib monother-
apy (75.0% (n=27)).
Co-primary endpoints
Treatment differences (90% CI) in RAMRIS BME at month 6
were −1.55 (−2.52 to −0.58) for tofacitinib with MTX and
−1.74 (−2.72 to −0.76) for tofacitinib monotherapy (both
p<0.01 vs MTX monotherapy; ﬁgure 2A). Corresponding
changes from baseline in RAMRIS synovitis score at month 3
were −0.63 (−1.58 to 0.31; p=0.27) and −0.52 (−1.46 to
0.41; p=0.36) (ﬁgure 2B).
Secondary and exploratory endpoints
RAMRIS
The treatment difference (90% CI) in RAMRIS BME at month 3
was −1.24 (−2.21 to −0.27) for tofacitinib with MTX
and −1.32 (−2.28 to −0.37) for tofacitinib monotherapy (both
p<0.05 vs MTX monotherapy). Signiﬁcant differences were
maintained to month 12 (ﬁgure 2A). Improvements from
baseline in RAMRIS synovitis were observed in all groups up to
month 12. While improvements were numerically greater in both
tofacitinib groups versus MTX monotherapy at all time points
assessed, differences were not generally signiﬁcant (ﬁgure 2B).
Less deterioration in RAMRIS erosion scores was noted from
month 1 onwards in patients receiving tofacitinib with MTX,
versus MTX monotherapy (ﬁgure 2C). Treatment differences
(90% CI) in RAMRIS erosions at month 6 were −0.71 (−1.29 to
−0.12) for tofacitinib with MTX (p<0.05 vs MTX) and −0.67
(−1.25 to −0.08) for tofacitinib monotherapy (p=0.06 vs
MTX). Corresponding changes at month 12 were −1.29 (−1.90
to −0.69) and −1.26 (−1.87 to −0.65; both p<0.001). Mean
values for all RAMRIS measures over time are presented in
online supplementary table S1.
Post hoc cumulative probability plots for RAMRIS endpoints
In general, more patients receiving tofacitinib showed regression
(ie, improvement <−SDC) in RAMRIS BME (month 6) and
synovitis (month 3) versus MTX monotherapy, and a smaller
proportion demonstrated progression (ie, deterioration >SDC)
(ﬁgure 3A,B). The MTX monotherapy group contained a greater
proportion of patients with deterioration of erosive damage at
month 12 versus both tofacitinib groups (ﬁgure 3C). This was
mirrored by a smaller proportion of patients with no progression
in van der Heijde mTSS (change ≤0.5) at month 12 in the MTX
monotherapy group versus either tofacitinib groups (ﬁgure 3D).
RAMRIQ and DCE MRI
Reductions from baseline in RAMRIQ BME and synovitis were
observed for both tofacitinib groups from month 1 to month 12
(ﬁgure 2D,E). Treatment differences were signiﬁcant (p<0.05
vs MTX monotherapy) through month 6 for BME and through
month 12 for synovitis (ﬁgure 2D,E). Treatment differences in
RAMRIQ bone erosion scores showed signiﬁcantly less deterior-
ation of erosive damage at months 6 and 12 in both tofacitinib
groups versus MTX monotherapy (all p<0.05) (ﬁgure 2F).
DCE MRI measurements (NVox) indicated signiﬁcant
improvements from baseline in synovitis at month 3 for both
tofacitinib groups (p<0.01 vs MTX monotherapy) (ﬁgure 2G).
Improvements remained signiﬁcant (p<0.05) through month
12 (ﬁgure 2G). Mean values for RAMRIQ and DCE MRI mea-
sures over time can be found in online supplementary table S1.
Least squares (LS) mean changes from baseline in IRE and EMax
are shown in online supplementary ﬁgure S1.
Radiographic assessments
Numerical changes from baseline in van der Heijde mTSS, joint
space narrowing and erosion component scores were small in all
treatment arms at months 6 and 12 (table 2).
Clinical response
Numerically higher ACR20, ACR50 and ACR70 response rates
were observed at months 3, 6 and 12 in the tofacitinib groups
versus MTX monotherapy (table 2). The proportion of patients
Table 2 Radiographic and clinical endpoints (evaluable set, LOCF)
Tofacitinib
10 mg twice
daily + MTX
Tofacitinib 10 mg
twice daily
monotherapy
MTX
monotherapy
LS mean change from baseline (SE)
van der Heijde mTSS
Month 6† 0.44 (0.50) −0.14 (0.51) 0.93 (0.52)
Month 12‡ 0.85 (0.51) −0.15 (0.52)* 1.36 (0.54)
JSN component score
Month 6† 0.29 (0.34) −0.06 (0.35) 0.35 (0.36)
Month 12‡ 0.43 (0.35) −0.12 (0.36) 0.71 (0.37)
Erosion component score
Month 6† 0.16 (0.24) −0.10 (0.25) 0.58 (0.25)
Month 12‡ 0.42 (0.25) −0.05 (0.26) 0.65 (0.27)
Responders, % (SE)
ACR20 N=35 N=36 N=37
Month 3 77.1 (7.1) 66.7 (7.9) 56.8 (8.1)
Month 6 77.1 (7.1)* 72.2 (7.5) 54.1 (8.2)
Month 12 82.9 (6.4) 66.7 (7.9) 56.8 (8.1)
ACR50 N=35 N=36 N=37
Month 3 48.6 (8.4) 55.6 (8.3)* 29.7 (7.5)
Month 6 57.1 (8.4)** 52.8 (8.3)* 27.0 (7.3)
Month 12 65.7 (8.0)** 50.0 (8.3) 35.1 (7.8)
ACR70 N=35 N=36 N=37
Month 3 25.7 (7.4) 27.8 (7.5) 13.5 (5.6)
Month 6 34.3 (8.0) 30.6 (7.7) 24.3 (7.1)
Month 12 28.6 (7.6) 33.3 (7.9) 24.3 (7.1)
DAS28-4(ESR) <2.6 N=34 N=36 N=37
Month 3 23.5 (7.3) 2.8 (2.7) 13.5 (5.6)
Month 6 29.4 (7.8) 13.9 (5.8) 13.5 (5.6)
Month 12 35.3 (8.2)* 19.4 (6.6) 13.5 (5.6)
DAS28-4(ESR) ≤3.2 N=34 N=36 N=37
Month 3 32.4 (8.0) 30.6 (7.7) 16.2 (6.1)
Month 6 41.2 (8.4) 27.8 (7.5) 21.6 (6.8)
Month 12 58.8 (8.4)*** 30.6 (7.7) 18.9 (6.4)
HAQ-DI improvement
≥0.22§
N=34 N=36 N=37
Month 3 73.5 (7.6) 75.0 (7.2) 81.1 (6.4)
Month 6 76.5 (7.3) 75.0 (7.2) 70.3 (7.5)
Month 12 73.5 (7.6) 72.2 (7.5) 73.0 (7.3)
*p<0.05, **p<0.01, ***p<0.001 vs MTX monotherapy.
†The numbers of patients evaluable at Month 6 were 29, 27 and 28 in the tofacitinib
with MTX, tofacitinib monotherapy and MTX monotherapy groups, respectively.
‡The numbers of patients evaluable at Month 12 were 26, 25 and 22 in the tofacitinib
with MTX, tofacitinib monotherapy and MTX monotherapy groups, respectively.
§Improvement vs baseline.
ACR, American College of Rheumatology response criteria; DAS28-4(ESR), Disease
Activity Score in 28 joints with 4 variables including erythrocyte sedimentation rate;
HAQ-DI, Health Assessment Questionnaire-Disability Index; JSN, joint space narrowing;
LOCF, last observation carried forward; LS, least squares; mTSS, van der Heijde
modification of the total Sharp score; MTX, methotrexate; N, number of patients with
values at baseline and time point of interest.
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who achieved DAS28-4(ESR) <2.6 increased over time in both
tofacitinib groups, whereas corresponding values in the MTX
monotherapy group remained low and stable (table 2). More
patients receiving tofacitinib (vs MTX monotherapy) achieved
DAS28-4(ESR) ≤3.2 from month 3 onwards (table 2).
Compared with MTX monotherapy, the proportion of patients
achieving an improvement in HAQ-DI ≥0.22 from baseline in
the tofacitinib groups was numerically higher at month 6 and
similar at month 12 (table 2).
Safety and tolerability
AEs were reported in 78.9% of patients (86/109), of which
96.1% (245/255) were mild or moderate. AEs are summarised
in table 3. Five patients had serious AEs, one of which (anal
abscess in a patient receiving tofacitinib with MTX) was
considered treatment-related by the investigator, resulted in
permanent discontinuation, and was the only serious
infection reported. No deaths were reported. Eleven patients
discontinued due to AEs (any cause). Liver function test
Table 3 Safety events and discontinuations (all causalities)
n (%)
Tofacitinib 10 mg twice
daily + MTX (N=36)
Tofacitinib 10 mg twice daily
monotherapy (N=36)
MTX monotherapy
(N=37)
Patients with TEAEs 25 (69.4) 31 (86.1) 30 (81.1)
Severity of TEAEs
Mild/moderate 89/93 (95.7) 83/88 (94.3) 73/74 (98.6)
Severe 4/93 (4.3) 5/88 (5.7) 1/74 (1.4)
Patients with serious TEAEs 2 (5.6) 1 (2.8) 2 (5.4)
Discontinuations 8 (22.2) 9 (25.0) 16† (43.2)
Discontinuations due to TEAEs 4 (11.1) 2 (5.6) 5 (13.5)
Most common TEAEs by SOC
Infections and infestations 14 (38.9) 10 (27.8) 9 (24.3)
Gastrointestinal disorders 9 (25.0) 11 (30.6) 10 (27.0)
Investigations 11 (30.6) 7 (19.4) 10 (27.0)
Skin and subcutaneous tissue disorders 5 (13.9) 7 (19.4) 5 (13.5)
Musculoskeletal and connective tissue disorders 4 (11.1) 6 (16.7) 6 (16.2)
Most common TEAEs occurring in ≥5% of patients in any group
Increased alanine aminotransferase 6 (16.7) 0 (0.0) 5 (13.5)
Hypertension 1 (2.8) 6 (16.7) 0 (0.0)
Gastritis 0 (0.0) 5 (13.9) 4 (10.8)
Rheumatoid arthritis 0 (0.0) 2 (5.6) 5 (13.5)
Rash 1 (2.8) 4 (11.1) 0 (0.0)
Alopecia 3 (8.3) 0 (0.0) 3 (8.1)
Headache 3 (8.3) 2 (5.6) 2 (5.4)
Pharyngitis 2 (5.6) 3 (8.3) 2 (5.4)
Upper respiratory tract infection 3 (8.3) 2 (5.6) 2 (5.4)
Blood creatinine phosphokinase increased 1 (2.8) 3 (8.3) 1 (2.7)
Bronchitis 3 (8.3) 0 (0.0) 0 (0.0)
Aspartate aminotransferase increased 2 (5.6) 1 (2.8) 3 (8.1)
Influenza 2 (5.6) 2 (5.6) 0 (0.0)
Urinary tract infection 2 (5.6) 2 (5.6) 0 (0.0)
Upper abdominal pain 2 (5.6) 1 (2.8) 2 (5.4)
Hypertransaminasaemia 2 (5.6) 1 (2.8) 1 (5.4)
Dyspepsia 2 (5.6) 1 (2.8) 1 (2.7)
Hepatic enzyme increased 2 (5.6) 1 (2.8) 2 (5.4)
Rhinitis 2 (5.6) 1 (2.8) 1 (2.7)
Diarrhoea 1 (2.8) 2 (5.6) 1 (2.7)
Hypertriglyceridaemia 1 (2.8) 1 (2.8) 2 (5.4)
Back pain 1 (2.8) 0 (0.0) 2 (5.4)
Gamma-glutamyl transferase increased 1 (2.8) 0 (0.0) 2 (5.4)
Gastroenteritis 2 (5.6) 0 (0.0) 0 (0.0)
Dry mouth 2 (5.6) 0 (0.0) 0 (0.0)
Transaminase increased 2 (5.6) 0 (0.0) 0 (0.0)
Weight increased 0 (0.0) 2 (5.6) 0 (0.0)
Menorrhagia 0 (0.0) 2 (5.6) 0 (0.0)
†Discontinuations due to: insufficient clinical response (n=6); AE (n=5; of which 3 were related to study drug); patient no longer willing to participate in study (n=3); and protocol
violation (n=2).
MTX, methotrexate; N, number of patients treated; n, number of unique patients with events; SOC, system organ class; TEAEs, treatment-emergent adverse events.
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abnormalities were the most common AE that resulted in dis-
continuation: two patients receiving tofacitinib with MTX,
and four patients receiving MTX monotherapy. Six patients
receiving MTX monotherapy discontinued due to insufﬁcient
clinical response—no tofacitinib-treated patients discontinued
for this reason.
There were few differences between treatment groups: nine
patients (8.3%) had severe AEs, of which eight (7.3%) were
randomised to tofacitinib (n=4 in each tofacitinib group); and
the proportion of patients with infections (any cause) was
higher for tofacitinib with MTX versus the monotherapy groups
(table 3).
DISCUSSION
This novel imaging study in patients with early RA provides evi-
dence that tofacitinib 10 mg twice daily, administered as mono-
therapy or in combination with MTX, can improve MRI
outcomes related to tissue inﬂammation that have been identi-
ﬁed as prognostic indicators for joint damage.1 40 All MRI
methodologies demonstrated reduced inﬂammation in the syno-
vium and bone marrow with tofacitinib. Numerical trends in
semiquantitative and quantitative MRI data were consistent
between the two tofacitinib arms. Furthermore, quantitative
methodologies identiﬁed signiﬁcant changes in MRI pathologies
(inﬂammation and erosive damage) as early as month 1 or 3,
and demonstrated suboptimal treatment-related suppression of
inﬂammation and progressive bone erosions with MTX mono-
therapy. The study met the ﬁrst of its co-primary endpoints,
with highly signiﬁcant improvements in RAMRIS BME at
month 6 observed for both tofacitinib groups versus MTX
monotherapy. Statistically signiﬁcant improvement in RAMRIS
synovitis at month 3 versus MTX monotherapy was not met.
However, numerical improvements in RAMRIS synovitis were
observed in both tofacitinib groups (vs MTX). Furthermore,
signiﬁcant improvements in synovitis scores were observed
over time with tofacitinib when quantitative methodologies
were used.
The concordance between results obtained using three
different MRI techniques underlines the effectiveness of MRI
in the evaluation of joint inﬂammation and damage. All mea-
sures were analysed blind to time order, adding to the robust-
ness of the evaluation. The improved differentiation of
tofacitinib groups from MTX monotherapy enabled by the
quantitative MRI techniques (compared with the semiquantita-
tive RAMRIS method) further validates their use as improved
tools for outcome assessment. RAMRIQ is still in develop-
ment, and increased responsiveness for bone pathologies is
expected.
In this study, changes from baseline in van der Heijde
mTSS were small in both tofacitinib groups. This ﬁnding,
together with the relative proportions of patients with progres-
sion in mTSS at month 12 in tofacitinib groups (vs MTX
monotherapy), is supportive of the lack of radiographic
progression noted in previous studies of tofacitinib as mono-
therapy, or in combination with MTX, in patients with
moderate-to-severe RA.14 15 In the present study, trends in
radiographic parameters at months 6 and 12 were consistent
with MRI data.
The safety and efﬁcacy of tofacitinib was consistent with
phase 3 studies of tofacitinib.11–16 No new safety signals were
identiﬁed in this study.
This was an exploratory study. The RAMRIS SDCs were cal-
culated from intraobserver readings, and this may result in more
favourable SDCs than those calculated from interobserver
readings. Additionally, the relatively small sample size (<40
patients per group) may have introduced certain limitations.
Furthermore, approximately half of the patients randomised to
MTX monotherapy failed to complete the study. It is possible
that had patients not been lost who were failing on MTX mono-
therapy, larger treatment differences would have been observed
for tofacitinib groups versus MTX monotherapy. However, a
separate analysis using last observation carried forward for
missing values produced ﬁndings that were consistent with those
of the evaluable set (not shown).
CONCLUSIONS
These results, obtained using a range of highly sensitive MRI
endpoints, and incorporating the validated RAMRIS technique
and novel quantitative techniques, provide consistent evidence
for the beneﬁts of tofacitinib in reducing inﬂammation in the
synovium and bone marrow, and inhibiting progression of struc-
tural damage in patients with early RA. The novel, quantitative
methods used here may, after further validation, prove more
sensitive and discriminating than conventional semiquantitative
scoring.
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